Urogenital disorders associated with oestrogen deficiency: the role of promestriene as topical oestrogen therapy

@article{Santos2010UrogenitalDA,
  title={Urogenital disorders associated with oestrogen deficiency: the role of promestriene as topical oestrogen therapy},
  author={Isabel Santos and Stephen P. Clissold},
  journal={Gynecological Endocrinology},
  year={2010},
  volume={26},
  pages={644 - 651}
}
Urogenital disorders associated with oestrogen deficiency affect many women throughout menopausal transition. Symptoms such as vaginal dryness, burning, pruritus, dyspareunia, urinary tract urgency/frequency and incontinence have a significant impact on the individual's quality of life. For younger and healthy menopausal women, systemic oestrogen replacement may improve both vasomotor and urogenital symptoms and will be the treatment of choice. However, a proportion of women on systemic therapy… 

The role of hormone therapy in urogenital health after menopause.

Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?

To improve promestriene safety, especially in estrogen-sensitive cancer patients, a very low dose is used from the beginning, starting from half or less of the usual dose, and then gradually increased till the minimum effective dose, which could further reduce its already minimal vaginal absorption.

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause

The daily intravaginal administration of 0.50% DHEA (Prasterone) has shown clinically and highly statistically significant effects on the four coprimary parameters suggested by the US Food and Drug Administration, thus showing the high benefit-to-risk ratio of this treatment based upon the novel understanding of the physiology of sex steroids in women.

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause

The daily intravaginal administration of 0.50% DHEA (Prasterone) has shown clinically and highly statistically significant effects on the four coprimary parameters suggested by the US Food and Drug Administration, thus showing the high benefit-to-risk ratio of this treatment based upon the novel understanding of the physiology of sex steroids in women.

Management of genitourinary syndrome of menopause in breast cancer survivors: An update

The present data suggest that these therapies are effective for VVA in BCSs; however, safety remains controversial and a there is a major concern with all of these treatments.

Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients

Cancer patients suffer from vaginal dryness and dyspareunia earlier and longer than the general population, with more severe and distressing symptoms, but the most effective therapy is use of vaginal estrogens.

Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue

Continuing investigations of various treatments for atrophic vaginitis are necessary and definitive results are needed pertaining to the safety of topical estrogens in breast cancer survivors.

Local hormone therapy for genitourinary syndrome of menopause in breast cancer patients: is it safe?

The worsening of QoL in patients due to symptoms related to GSM can lead to discontinuation of hormone adjuvant therapies and therefore must be addressed properly, according to health care professionals.

Hormone Replacement Therapy in Premature Ovarian Insufficiency

Early loss of ovarian function can present insidiously with occasional periods of recovery, and it should be identified as premature ovarian insufficiency (POI), and cases with sudden, definitive onset (due to bilateral ovariectomy or treatments usually related to oncological conditions) should be considered premature ovarian failure (POF).

References

SHOWING 1-10 OF 42 REFERENCES

Absence of systemic hormonal effects in an oestradiol diether topically active on the vaginal mucosa.

Dyspareunia in postmenopausal women: a critical review.

Empirical evidence suggests that dyspareunia is common in postmenopausal women, and that it is not highly correlated with menopausal status, estrogen levels or vaginal atrophy, and a change in perspective toward a multiaxial pain-focused approach is proposed for future research concerning dysPareunia in post menopausal women.

Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?

The urogenital consequences of estrogen deprivation therapy in breast cancer patients is focused on and a simple guide of current and future strategies for managing these symptoms is provided.

Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview

The role, safety and effectiveness of topical vaginal estrogen therapy are provided, which reverse atrophic changes and relieve associated symptoms, while avoiding systemic effects.

The effects of hormones on urinary incontinence in postmenopausal women

  • S. QuinnC. Domoney
  • Medicine, Biology
    Climacteric : the journal of the International Menopause Society
  • 2009
The evidence for the effects of estrogen on the postmenopausal urogenital tract is examined and a number of randomized, placebo-controlled trials have concluded that estrogens should not be used for the treatment of urge or stress incontinence.

Hormone replacement therapy in menopausal women: Past problems and future possibilities

There is evidence that estriol, by binding preferentially to estrogen receptor-β, may inhibit some of the unwanted effects of estradiol, which is an increasingly popular alternative hormone therapy used for menopausal symptoms.

Should symptomatic menopausal women be offered hormone therapy?

Symptom relief with hormone therapy for many younger women (at the onset of menopause) with menopausal symptoms outweighs the risks and may provide an overall improvement in quality of life.

Menopause and sexuality: prevalence of symptoms and impact on quality of life.

The detection and management of vaginal atrophy